ATE402152T1 - Hiv-inhibierende1,2,4-triazine - Google Patents

Hiv-inhibierende1,2,4-triazine

Info

Publication number
ATE402152T1
ATE402152T1 AT04708367T AT04708367T ATE402152T1 AT E402152 T1 ATE402152 T1 AT E402152T1 AT 04708367 T AT04708367 T AT 04708367T AT 04708367 T AT04708367 T AT 04708367T AT E402152 T1 ATE402152 T1 AT E402152T1
Authority
AT
Austria
Prior art keywords
hiv
triazine
inhibiting
Prior art date
Application number
AT04708367T
Other languages
English (en)
Inventor
Paulus Joannes Lewi
Paul Adriaan Janssen
Jonge Marc Rene De
Lucien Maria Henricus Koymans
Hendrik Maarten Vinkers
Frederik Frans Desire Daeyaert
Jan Heeres
Ruben Gerardus George Leenders
Georges Joseph Corne Hoornaert
Amuri Kilonda
Donald W Ludovici
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE402152T1 publication Critical patent/ATE402152T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furnace Details (AREA)
AT04708367T 2003-02-07 2004-02-05 Hiv-inhibierende1,2,4-triazine ATE402152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0301289 2003-02-07

Publications (1)

Publication Number Publication Date
ATE402152T1 true ATE402152T1 (de) 2008-08-15

Family

ID=32892827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04708367T ATE402152T1 (de) 2003-02-07 2004-02-05 Hiv-inhibierende1,2,4-triazine

Country Status (20)

Country Link
US (1) US7585861B2 (de)
EP (1) EP1597242B1 (de)
JP (1) JP4783725B2 (de)
KR (1) KR20050105190A (de)
CN (2) CN102503903A (de)
AP (1) AP2005003365A0 (de)
AT (1) ATE402152T1 (de)
AU (1) AU2004213173B2 (de)
BR (1) BRPI0407306A (de)
CA (1) CA2513123C (de)
DE (1) DE602004015254D1 (de)
EA (1) EA010379B1 (de)
ES (1) ES2311146T3 (de)
HR (1) HRP20050690A2 (de)
IL (1) IL170120A (de)
MX (1) MXPA05008368A (de)
NO (1) NO20054127L (de)
PL (1) PL232814B1 (de)
WO (1) WO2004074266A1 (de)
ZA (1) ZA200506254B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2543376A1 (de) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazin Kinasehemmer
US7923554B2 (en) * 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
AU2008210455A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
ES2402087T3 (es) 2008-07-23 2013-04-26 Vertex Pharmaceuticals Incorporated Inhibidores de la pirazolopiridina quinasa
CA2732765A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
CA2760705A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
JP5769733B2 (ja) 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ピラゾロピリジンキナーゼ阻害剤
EP2582702A1 (de) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidinkinasehemmer
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2021071984A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
CN111333543B (zh) * 2020-04-17 2022-09-16 武汉工程大学 一种利匹韦林中间体的合成方法
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺
CN117658936B (zh) * 2023-11-30 2025-06-06 上海予君生物科技发展有限公司 一种3,5,6-三氯-[1,2,4]-三嗪的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
BR9611562A (pt) 1995-11-23 1999-03-02 Janssen Pharmaceutica Nv Misturas sólidas de ciclodextrinas preparadas via extrusão sob fusão
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
EP0945447A1 (de) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
EA002973B1 (ru) * 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
CN1295567A (zh) 1998-03-27 2001-05-16 株式会社Lg化学 作为新型抗氧剂的聚乙氧基化抗坏血酸衍生物及其制备方法
SK287270B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
SI1129079T1 (sl) * 1998-11-10 2006-06-30 Janssen Pharmaceutica Nv 2,4-disubstituirani triazinski derivati z anti-HIV aktivnostjo
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
US7105522B2 (en) 2001-03-15 2006-09-12 Janssen Pharmaceutica, N.V. HIV inhibiting pyrazinone derivatives
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز

Also Published As

Publication number Publication date
EP1597242B1 (de) 2008-07-23
JP2006516983A (ja) 2006-07-13
KR20050105190A (ko) 2005-11-03
IL170120A (en) 2013-04-30
CN102503903A (zh) 2012-06-20
AU2004213173A1 (en) 2004-09-02
EA200501268A1 (ru) 2006-02-24
PL232814B1 (pl) 2019-07-31
JP4783725B2 (ja) 2011-09-28
PL378107A1 (pl) 2006-03-06
CA2513123A1 (en) 2004-09-02
CA2513123C (en) 2013-04-23
HRP20050690A2 (en) 2006-08-31
US20070037811A1 (en) 2007-02-15
EP1597242A1 (de) 2005-11-23
WO2004074266A8 (en) 2004-11-11
MXPA05008368A (es) 2005-11-04
NO20054127L (no) 2005-09-05
WO2004074266A1 (en) 2004-09-02
BRPI0407306A (pt) 2006-02-21
ES2311146T3 (es) 2009-02-01
AP2005003365A0 (en) 2005-09-30
AU2004213173B2 (en) 2010-07-29
CN1747941A (zh) 2006-03-15
US7585861B2 (en) 2009-09-08
ZA200506254B (en) 2008-02-27
DE602004015254D1 (de) 2008-09-04
EA010379B1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
ATE402152T1 (de) Hiv-inhibierende1,2,4-triazine
CY2014041I2 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
NO20041144L (no) Gassloftingsventil.
NO20053248D0 (no) Kerosenblanding.
FI20030261A0 (fi) Iskulaite
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
NO20052248D0 (no) Svivelstykkesystem.
FI20020881A0 (fi) Iskulaite
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
ITMI20032170A1 (it) Tagliacimosse.
NO20051497D0 (no) Beta-laktamaseinhibitorprodrug.
ITMI20030916A1 (it) Lancetta.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ES1052590Y (es) Quiosco-consigna.
SE0301847D0 (sv) Novel 3,3-Diphenylpropylamines
ES1053097Y (es) Envase-expositor mejorado.
ITTE20030006U1 (it) Arrostimatic 60
ES1054229Y (es) Canape mejorado.
ES1053039Y (es) Tendedero de fuelle mejorado.
ES1051110Y (es) Caja-palet.
ES1052945Y (es) Contraventana.
ES1052938Y (es) Cantonera.
ES1051605Y (es) Cromo-puzzle.
ES1051703Y (es) Potera.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties